Calidi Biotherapeutics (NYSEAMERICAN:CLDI) Trading Up 0.6% – Here’s What Happened

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI)’s stock price was up 0.6% during trading on Wednesday . The stock traded as high as $0.2958 and last traded at $0.2706. Approximately 5,383,457 shares were traded during trading, an increase of 776% from the average daily volume of 614,526 shares. The stock had previously closed at $0.2691.

Calidi Biotherapeutics Trading Up 0.6%

The company has a market capitalization of $2.95 million, a P/E ratio of -0.04 and a beta of 1.42. The stock’s 50 day moving average is $0.50 and its 200-day moving average is $1.06. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.59 and a quick ratio of 1.59.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last released its quarterly earnings results on Friday, March 27th. The company reported $0.45 earnings per share (EPS) for the quarter. As a group, equities research analysts anticipate that Calidi Biotherapeutics, Inc. will post -4.48 earnings per share for the current year.

Hedge Funds Weigh In On Calidi Biotherapeutics

Institutional investors have recently bought and sold shares of the stock. Warberg Asset Management LLC bought a new position in Calidi Biotherapeutics in the third quarter worth about $28,000. Virtu Financial LLC bought a new position in Calidi Biotherapeutics in the fourth quarter worth about $25,000. Geode Capital Management LLC raised its stake in Calidi Biotherapeutics by 41.7% in the fourth quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock worth $49,000 after buying an additional 12,334 shares in the last quarter. Finally, DRW Securities LLC bought a new position in Calidi Biotherapeutics in the fourth quarter worth about $173,000. 12.53% of the stock is owned by institutional investors.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.